Created with Sketch.
57 minutes | Jan 24, 2020
48: We are all going to die
In which our heroes discuss the impending doom coming from Wuhan. Also wtf FDA re SRPT? 00:40 - We survived JPM! 05:00 - Are we all going to die form Coronavirus? 22:43 - The Goop series on Netflix 26:22 - Amarin has the one oil to rule them all 35:58 - Will the Sarepta madness lead to Biogen getting aducanumab approval? 47:58 - Does mixing cough syrup with wellbutrin make sense?
36 minutes | Oct 23, 2019
47: The amyloid hypothesis will outlive all of us.
In which we welcome our new commentator Wiktoria, and discuss the new BIIB shuck and jive.
51 minutes | Oct 17, 2019
46: The interesting Relmada data in depression and some balance sheet disasters
Discuss the recent Relmada data, Geovax, Amyris, WeWork and more: 01:15: RLMD data in TRD 13:23 The GOVX disaster 18:52 WeWork is being flushed down the toilet 24:08 Will HR3 passage actually mean fewer drugs will be developed? 29:49 Don't worry about red meat and geese deserve what they get 37:58 Who defends Theranos? 45:10 AMRS finally is up to date on filings and it isn't pretty
53 minutes | Oct 9, 2019
45: The hysteria around vaping and does Purdue really deserve to go bankrupt?
People need some perspective on vaping and these opioid lawsuit liabilities are out of control and will hurt patients. Here is a table of contents: 1:08 The hysteria around vaping 14:44 A new penile traction device for Peyronie's 16:38 Does SmileDirectClub make sense? 23:35 Aveo, really? 27:07 Does Purdue deserve to go bankrupt because of the opioid epidemic 45:08 A fountain of youth cocktail that includes two steroids and metformin 49:10 Alkaline water with some lemon
42 minutes | Aug 15, 2019
44: FDA has its hands full with Novartis, Amarin and people drinking bleach
Novartis gives the FDA a headache, the FDA then gives Amarin a headache and people are trying to cure their problems with bleach. 00:42 Novartis cheated 18:47 There are two FDA's, one for AMRN and another for everyone else 30:00 Don't drink bleach 33:57 Don't have a pedo island
39 minutes | Aug 5, 2019
43: Interview with Thomas Meyer, CEO of Auris Medical
We discuss Auris Medical’s development programs for intranasal betahistine for acute vertigo as well as to treat some of the major side effects of antipsychotic medication. 01:07 Auris’s AM-125 program for acute vertigo 16:57 The Phase II trial design for AM-125 26:47 AM-201 for antipsychotic-induced weight gain and drowsiness 34:38 The design of the Phase Ib trial for AM-201 and what to expect
41 minutes | Jul 29, 2019
42: Interview with Stephane Piat, CEO of Carmat
We discuss Carmat's total artificial heart, the technology, approval pathways and commercial potential 00:42 Carmat’s total artificial heart, the history and the technology 08:54 The data so far 18:00 The coming technological advances 20:49 The clinical development process 23:32 The commercial and reimbursement landscape 26:48 What happens with patients? 30:22 Will Carmat need a partner?
23 minutes | Jul 22, 2019
41: On vomit boat trials and Elon Musk
Why would anyone sign up for a vomit boat trial or get thousands of electrodes implanted into their brains? 00:41 The VNDA vomit boat trial 09:14 More on the KPTI approval 11:52 Elon Musk's Neuralink 18:44 Netflix has peaked
39 minutes | Jul 16, 2019
40: Interview with Daniel Schneider, CEO of Photocure
We cover Photocure’s marketed bladder cancer diagnostic product Hexvix/Cysview, its data and potential for growth in the United States and the prospects for future competition. 01:03 – What does Photocure do? 13:49 – How do the US and EU markets differ? 16:28 – The growth potential in the US market? 25:43 – Prospects for competition 32:32 – The recent licensing deal for Cevira
44 minutes | Jul 11, 2019
39: Biotech, a magical land of mystery
Why did selinexor get approved? What's going on with Roche/Spark? Why did ITCI have crazy results? Also a farewell. 00:37 Michael Becker RIP 02:22 What's up with the $KPTI approval 14:19 Some confusing $ITCI data 23:21 Why is the FTC taking so long to approve the Roche/Spark acquisition? 28:46 How did Jeff Epstein get so rich? It makes no sense
48 minutes | Jul 1, 2019
38: Vyleesi, of house Palatin, second of its kind, and mother of scams
Also ABBV buys a company, and why academia sucks. 00:30 - Vyleesi is the worst drug ever approved 23:27 - Abbvie buys Allergan 32:30 - Twitter censors tesladeaths.com 34:14 - CRISPR babies in Russia? 37:39 - Nat has a theory 40:47 - The cabal restraining innovation in the treatment of Alzheimer's
53 minutes | Jun 24, 2019
37: Cymabay's NASH disaster and some financings that burned investors
Can anyone really beat diet and exercise for NASH? Also, buyer beware. Here is some more detail on what we talk about: 00:39 Cymabay's disastrous NASH data, you're really better off with diet and exercise 17:25 Ampion screws some investors 36:50 Biohaven reminds investors that just because you cancel a conference presentation doesn't mean you are being bought 46:27 Evolution
43 minutes | Jun 10, 2019
36: KRAS for cancer and Enbrel for Alzheimer's
00:37 KRAS a hit at ASCO 08:59 Enbrel for Alzheimer's? 20:49 You don't need to take 10,000 steps a day 24:58 Satanic messages from Google Translate 27:30 What is up with the ARK model on TSLA? 31:07 Gamestop has a really bad quarter 35:09 FGEN has one of the worst calls ever
41 minutes | May 20, 2019
35: Interview with Yuval Cohen, CEO of Corbus Pharmaceuticals
An interview of Yuval Cohen, CEO of Corbus Pharmaceuticals where we discuss the cannabinoid space as well as the Corbus pipeline
39 minutes | May 13, 2019
34: Getting figged by Ovid and Cytokine
Another what's wrong with people sort of episode: 01:00 CYTK fails in Phase II but moves forward anyway 06:40 OVID insults analysts 18:42 Figging. Why? 24:05 MNK bribes doctors 28:35 TSLA and Peloton
38 minutes | Apr 29, 2019
33: Moleculin be swindlin?
Also we bid farewell to Briana. 02:05 Was the MBRX pump on purpose? 06:17 TSLA lost 4 board members on Good Friday 12:52 AMRS was in default for a day, also announced on Good Friday 17:00 Macro/financial system stuff 27:22 The IQVIA report on R&D 34:28 The Yang gang is nuts
45 minutes | Apr 15, 2019
32: An ode to animal research; ZGNX and Planet of the Apes
Also the trajectory of GILD and eyes full of bees. 00:43 Refusal to file letter for ZGNX 14:30 Weirdness with AMRS 27:00 Chinese scientists give human intelligence genes to monkeys 34:48 Bees living off of a woman's tears 36:48 GILD has layoffs
50 minutes | Mar 25, 2019
31: Biogen blows it big time
On the Sisyphean struggle that is the amyloid hypothesis. Also, space herpes. 00:28 Biogen blows up 21:00 Should Biogen buy Sage? 33:10 Another nutritional cohort study 42:55 Space herpes (watch out Elon Musk)
48 minutes | Mar 18, 2019
30: Gottlieb will always be my sugar loaf
In which our heroes discuss Scott Gottlieb leaving, the new Theranos movie, and the risks of cutting sugar loaf. 01:02 Scott Gottlieb is leaving the FDA 10:35 The Inventor documentary on Theranos 18:00 College bribery admissions scandal 27:45 Is Esketamine a dud? 36:00 Mechanisms of penile fracture in Western Iran 41:45 A 15 gram infusion of Vitamin C?
40 minutes | Mar 4, 2019
29: ONCE in a lifetime, same as it ever was
In which our heroes discuss Roche's motivations with Spark. Also musings on senate subcommittees and goat wine. 00:43 Spark gets bought 04:40 Senate drug pricing hearing 16:22 The ER is an interesting place 24:13 Karyopharm's panel 29:19 Bionic mice
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2022